Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the ...
Harrow (NASDAQ: HROW) announced on Tuesday that it intends to offer an additional $50M in 8.625% senior unsecured notes due 2030, subject to market and other conditions. The company said the notes ...
Harrow has the U.S. commercial rights to 10 branded ophthalmic pharmaceutical products approved by the Food and Drug Administration (FDA). Harrow also owns ImprimisRx, a leading U.S.
Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that ...
NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced the launch of its “Harrow Cares” program through a strategic ...
Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that ...
Please provide your email address to receive an email when new articles are posted on . Harrow will inherit MELT-300, a sublingually delivered sedation product. The company plans to submit a new drug ...
Boll stated, "we are updating our full year revenue outlook to a range of $270 million to $280 million." He noted, "While our original target is still within reach, this new range is one I believe we ...
(RTTNews) - Harrow, Inc. (HROW), an ophthalmic disease solutioning firm, reaffirmed its full-year 2025 revenue guidance, along with announcements on management, commercial and development program ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results